Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Common Equity (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Common Equity for 16 consecutive years, with $528.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 0.94% to $528.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $528.1 million, a 0.94% decrease, with the full-year FY2024 number at $532.1 million, up 7.02% from a year prior.
  • Common Equity was $528.1 million for Q3 2025 at Usana Health Sciences, down from $531.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $533.1 million in Q3 2024 to a low of $389.9 million in Q2 2022.
  • A 5-year average of $462.7 million and a median of $462.1 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: grew 26.82% in 2021, then decreased 10.53% in 2022.
  • Usana Health Sciences' Common Equity stood at $399.1 million in 2021, then increased by 8.87% to $434.5 million in 2022, then increased by 14.44% to $497.2 million in 2023, then rose by 7.02% to $532.1 million in 2024, then decreased by 0.76% to $528.1 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Common Equity are $528.1 million (Q3 2025), $531.1 million (Q2 2025), and $529.8 million (Q1 2025).